HikalQ3 FY24

Hikal Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹217.94P/E: 37.8Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Revenue and margins expected to pick up from the second half of FY '25, reaching pre-COVID levels.
  • Pharma business volumes and margins are recovering, with a full revival anticipated by H2 FY '25.
  • Crop Protection currently faces destocking, expected to normalize and improve from Q3 or Q4 of the next financial year (FY '25).
  • Medium to long-term industry fundamentals remain intact despite short-term challenges.
  • Double-digit revenue growth expected post-normalization, targeting INR 3,000+ crores by FY '27–'28 from INR 2,000+ crores currently.
  • Focus on growing CDMO business significantly, with a rising share in overall revenue expected over the next 3-4 years.
  • Animal Health segment projected to contribute INR 200-300 crore revenue within 3-4 years, with ramp-up beginning FY '25.
  • Continuous new product launches in Pharma (3-4 products annually) supporting growth.
  • Capex of INR 200 crore planned for FY '24, aiding capacity expansion and future growth.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any ongoing or planned new fundraising through debt or equity in the provided transcript.
  • The discussion about funding challenges mainly pertains to the pharma space, especially funding for Phase I/II molecules and smaller biotech customers facing slowdowns.
  • Hikal management stated they are not deeply involved in Phase II, III funding challenges and did not indicate any need to raise funds currently.
  • Capex plans are primarily funded through internal resources, with INR200 crores planned for the current year and INR500 crores CWIP ongoing.
  • No indications or announcements related to new equity or debt fundraising were discussed during the Q&A or management commentary.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Hikal Limited is undertaking significant capital expenditure (capex), targeting INR 200 crores in the current financial year, with about INR 170 crores already incurred and the balance expected soon.
  • A major ongoing project is the commissioning of a new multipurpose plant at Panoli, part of an INR 500 crores investment MoU signed with the Gujarat government.
  • This new plant is anticipated to be operational by Q1 or Q2 of the coming quarters and will primarily cater to crop protection with a focus on backward integration.
  • Future capex beyond the current year is expected to be moderate, with INR 30-40 crores planned in the next quarter.
  • The company aims to fully capitalize and operationalize the INR 500 crores CWIP with total capex over two years expected to be around INR 700 crores.
  • These investments are strategic, aimed at growing the CDMO business and enhancing long-term capacities across pharma, animal health, and crop protection segments.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHikal
Rev 3Mar 1

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →